Pharmathene Inc. won another moral victory when the Delaware Court of Chancery issued a ruling in its long-running dispute with Siga Technologies Inc. over the smallpox antiviral, tecovirimat. The court awarded Annapolis, Md.-based Pharmathene a lump sum payment – though the amount from a complex payment formula remains to be seen – for damages arising from the value of lost profits from sales of tecovirimat (previously ST-246 and Arestvyr).